Reactions 1491, p9 - 8 Mar 2014

(85.7%) and the [hepatic arterial infusion] catheter andsubcutaneous implantable port system had to be removed." SAntineoplasticsTajima H, et al. Hepatic arterial infusion chemotherapy with gemcitabine and

Various toxicities: 7 case reports 5-fluorouracil or oral S-1 improves the prognosis of patients with postoperativeliver metastases from pancreatic cancer. Molecular and Clinical Oncology 1:In a study, 7 patients with liver metastases from pancreatic869-874, No. 5, Sep 2013. Available from: URL: http://doi.org/10.3892/cancer developed various toxicities while receiving hepaticmco.2013.152 - Japan 803100176arterial infusion chemotherapy with gemcitabine and either

fluorouracil or gimeracil/oteracil/tegafur [some routes notstated; duration of therapy before reaction onsets andoutcomes not stated]; all patients eventually died from theirprimary disease.

A 61-year-old woman received intrahepatic arterial infusionchemotherapy, with each biweekly cycle comprisinggemcitabine 400mg/standard liver volume dissolved in saline50mL administered over 30 minutes, then fluorouracil 250mg/standard liver volume dissolved in saline 50mL infusedcontinuously over 24 hours on days 1–5. During therapy shedeveloped grade 2 anaemia, grade 3 leucopenia and grade 2thrombocytopenia, and catheter complications leading toremoval of the subcutaneous implantable port system.

A 62-year-old man received intrahepatic arterial infusionchemotherapy, with each biweekly cycle comprisinggemcitabine 800mg/standard liver volume dissolved in saline50mL administered over 30 minutes, then fluorouracil 250mg/standard liver volume dissolved in saline 50mL infusedcontinuously over 24 hours on days 1–5. During therapy hedeveloped grade 2 anaemia, grade 1 thrombocytopenia, andcatheter complications leading to removal of the subcutaneousimplantable port system.

A 69-year-old man received intrahepatic arterial infusionchemotherapy, with each biweekly cycle comprisinggemcitabine 800mg/standard liver volume dissolved in saline50mL administered over 30 minutes, then fluorouracil 250mg/standard liver volume dissolved in saline 50mL infusedcontinuously over 24 hours on days 1–5. During therapy hedeveloped grade 1 anaemia.

A 71-year-old man received intrahepatic arterial infusionchemotherapy, with each biweekly cycle comprisinggemcitabine 800mg/standard liver volume dissolved in saline50mL administered over 30 minutes, then fluorouracil 250mg/standard liver volume dissolved in saline 50mL infusedcontinuously over 24 hours on days 1–5. During therapy hedeveloped grade 1 anaemia, grade 2 thrombocytopenia, andcatheter complications leading to removal of the subcutaneousimplantable port system.

A 60-year-old woman received intrahepatic arterial infusionchemotherapy, with each biweekly cycle comprisinggemcitabine 800mg/standard liver volume dissolved in saline50mL administered over 30 minutes, then fluorouracil 250mg/standard liver volume dissolved in saline 50mL infusedcontinuously over 24 hours on days 1–5. During therapy shedeveloped grade 2 anaemia, and catheter complicationsleading to removal of the subcutaneous implantable portsystem.

A 66-year-old man received intrahepatic arterial infusionchemotherapy, with each biweekly cycle comprisingintrahepatic arterial infusion chemotherapy, with eachbiweekly cycle comprising gimeracil/oteracil/tegafur60 mg/m2/day for 7 consecutive days and gemcitabine 800mg/standard liver volume on day 8. During therapy, he developedgrade 2 anaemia, grade 2 leucopenia and grade 1thrombocytopenia. Catheter complications occurred, leadingto removal of the subcutaneous implantable port system.

A 65-year-old man received intrahepatic arterial infusionchemotherapy, with each biweekly cycle comprisingintrahepatic arterial infusion chemotherapy, with eachbiweekly cycle comprising gimeracil/oteracil/tegafur60 mg/m2/day for 7 consecutive days and gemcitabine 800mg/standard liver volume on day 8. During therapy, he developedgrade 1 anaemia and catheter complications, which lead toremoval of the subcutaneous implantable port system.

Author comment: "[T]here were no life-threateningtoxicities. However, catheter-related complications (arterialthrombosis or catheter dislocation) occurred in 6 cases

1

Reactions 8 Mar 2014 No. 14910114-9954/14/1491-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved